Operative sequentiality in tumor differentiation and progression as protein molecular structure and sequence context in modulating alternative splicing events


This review article discusses dimensional reconstruction of alternative splicing that not only affects primarily the distributional dimensions of isoforms of various protein species but especially influences the nature of interactivity events between various protein species and also the structure of the given protein molecules. In such terms, disorders of differentiation of individual tumors and of tumor types and subtypes would correlate with distinctive dimensions of expression of a limited number of genes in various modes of expressed selectivity programs. In particular, the differentiation programs of normal tissues would correlate with combinatorial systems of splicing factors and of auxiliary factors in the development of patterns of gene expression. The significance of mis-splicing events is consonant with the wide range of phenotypic expression of neoplastic lesions and in the great variety of differentiation patterns and also of the variable degrees of differentiation of various components of a given neoplasm. The structure of given protein isoforms resulting from alternative splicing correlate with the sequence context of exons in the enhancement or inhibition of splicing events and would also influence pathobiologic behavior patterns of given neoplastic lesions. The development of abnormal cell signalling pathways and of interactivity patterns in a combinatorial way would directly influence the stability and trafficking dynamics of given protein molecular species in inducing an abundance of protein isoform production. Series of multi-component systems ranging from receptivity to consequential pathways of development of differential phenotype would allow for a high degree of modulatory effect within systems implicating in particular the interactions of individual tumor cells with each other and with the matrix components. It is within the context of constitutive versus alternative splicing events that this review article proposes that proportional recreation of differentiation pathways promotes a self-progression of the pathobiologic processes of a given neoplastic lesion.

Share and Cite:

Agius, L. (2013) Operative sequentiality in tumor differentiation and progression as protein molecular structure and sequence context in modulating alternative splicing events. Open Journal of Genetics, 3, 83-88. doi: 10.4236/ojgen.2013.32010.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Huelga, S.C., Vu, A.Q., Arnold, J.D., Liang, T.Y., Liu, P.P., Yan, B.Y., et al. (2012) Integrative genome-wide analysis reveals cooperative regulation of alternative splicing by hn RNP proteins. Cell Reports, 1, 167-178. doi:10.1016/j.celrep.2012.02.001
[2] Hirschi, B. and Kolligs, F.T. (2013) Alternative splicing of BRAF transcripts and characterization of C-terminally truncated B-Raf isoforms in colorectal cancer. International Journal of Cancer, 133, 590-596. doi:10.1002/ijc.28061
[3] Raso-Barnett, L., Banky, B., Barbai, T., Becsagh, P., Timar, J. and Raso, E. (2013) Demonstration of a melanoma-specific CD44 alternative splicing pattern that remains qualitatively stable, but shows quantitative changes during tumor progression. PLoS One, 8, e53883. doi:10.1371/journal.pone.0053883
[4] Warzecha, C.C. and Carstens, R.P. (2012) Complex changes in alternative pre-m RNA splicing may play a central role in the epithelial-to-mesenchymal transition (EMT). Seminars in Cancer Biology, 22, 417-427. doi:10.1016/j.semcancer.2012.04.003
[5] Finley, S.D. and Popel, A.S. (2012) Predicting the effects of anti-angiogenic agents targeting specific VEGF isoforms. AAPS Journal, 14, 500-509.
[6] Tang, X., Li, J., Yu, B., Su, L., Yu, Y., Yan, M., et al. (2013) Osteopontin splice variants differentially exert clinicopathological features and biological functions in gastric cancer. International Journal of Biological Sciences, 9, 55-66. doi:10.7150/ijbs.5280
[7] Ben-Hur, V., Denichenko, P., Siegfried, Z., Maimon, A., Krainer, A., Davidson, B., et al. (2013) S6K1 alternative splicing modulates its oncogenic activity and regulates mTORC1. Cell Reports, 3, 103-115. doi:10.1016/j.celrep.2012.11.020
[8] Yang, W. and Yee, A.J. (2013) Versican V2 isoform enhances angiogenesis by regulating endothelial cell activities and fibronectin expression. FEBS Letters, 587, 185-192. doi:10.1016/j.febslet.2012.11.023
[9] Tabu, K., Bizen, N., Taga, T. and Tanaka, S. (2013) Gene regulation of prominin-1 (CD133) in normal and cancerous tissues. Advances in Experimental Medicine and Biology, 777, 73-85. doi:10.1007/978-1-4614-5894-4_5
[10] Das, S., Anczukow, O., Akerman, M. and Krainer, A.R. (2012) Oncogenic splicing factor SRSF1 is a critical transcriptional target of MYC. Cell Reports, 1, 110-117. doi:10.1016/j.celrep.2011.12.001
[11] Kim, I., Kwak, H., Lee, H.K., Hyun, S. and Jeong, S. (2012) Beta-catenin recognizes a specific RNA motif in the cyclooxygenase-2 m RNA 3’-UTR and interacts with HUR in colon cancer cells. Nucleic Acids Research, 40, 6863-6872. doi:10.1093/nar/gks331
[12] Alagaratnam, S., Harrison, N., Bakken, A.C., Hoff, A.M., Jones, M., Sveen, A., et al. (2013) Transforming pluripotency: An exon-level study of malignancy-specific transcripts in human embryonal carcinoma and embryonic stem cells. Stem Cells and Development, 22, 1136-1146. doi:10.1089/scd.2012.0369
[13] Saitoh, M. and Miyazawa, K. (2012) Transcriptional and post-transcriptional regulation in TGF-Beta-mediated epithelial-mesenchymal transition. The Journal of Biochemistry, 151, 563-571. doi:10.1093/jb/mvs040
[14] Cohen-Eliav, M., Golan-Gerstl, R., Siegfried, Z., Andersen, C.L., Torsen, K., Orntoft, T.F., et al. (2012) The splicing factor SRSF6 is amplified and is an oncoprotein in lung and colon cancers. The Journal of Pathology, 229, 630-639.
[15] Schultz, J.C., Vu, N., Shultz, M.D., Mba, M.U., Shapiro, B.A. and Chalfant, C.E. (2012) The proto-oncogene PKC1 regulates the alternative splicing of Bcl-x Pre-m RNA. Molecular Cancer Research, 10, 660-669. doi:10.1158/1541-7786.MCR-11-0363
[16] Wan, J. (2012) Antisense-mediated exon skipping to shift alternative splicing to treat cancer. Methods in Molecular Biology, 867, 201-208. doi:10.1007/978-1-61779-767-5_13
[17] Spitali, P. and Aartsma-Rus, A. (2012) Splice modulating therapies for human disease. Cell, 148, 1085-1088. doi:10.1016/j.cell.2012.02.014
[18] Di Modugno, R., Iapicca, P., Boudreau, A., Mottolese, M., Terrenato, I., Perracchio, L., et al. (2012) Splicing program of human MENA produces a previously undescribed isoform associated with invasive, mesenchymal-like breast tumors. Proceedings of the National Academy of Sciences of the United States of America, 109, 19280-19285. doi:10.1073/pnas.1214394109
[19] Li, G., Bahn, J.H., Lee, J.H., Peng, G., Chen, Z., Nelson, S.F., et al. (2012) Identification of allele-specific alternative m RNA processing via transcriptome sequencing. Nucleic Acids Research, 40, e104. doi:10.1093/nar/gks280
[20] Carpenter, R.L. and Lo, H.W. (2012) Identification, functional characterization and pathobiological significance of GLI1 isoforms in human cancers. Vitamins & Hormones, 88, 115-140.
[21] Bonnal, S., Vigevani, L. and Valcarcel, J. (2012) The spliceosome as a target of novel antitumour drugs. Nature Reviews Drug Discovery, 11, 847-859. doi:10.1038/nrd3823
[22] Miura, K., Fujibuchi, W. and Unno, M. (2012) Splice isoforms as therapeutic targets for colorectal cancer. Carcinogenesis, 33, 2311-2319. doi:10.1093/carcin/bgs347
[23] Niland, C.N., Merry, C.R. and Khalil, A.M. (2012) Emerging roles for long non-coding RNAs in cancer and neurological disorders. Frontiers in Genetics, 3, 25. doi:10.3389/fgene.2012.00025
[24] Carpenter, R.L. and Lo, H.W. (2012) Hedgehog pathway and GLI1 isoforms in human cancer. Discovery Medicine, 13, 105-113.
[25] Dardenne, E., Pierredon, S., Driouch, K., Gratadou, L., Lacroix-Triki, M., Espinoza, M.P., et al. (2012) Splicing switch of an epigenetic regulator by RNA helicases promotes tumor-cell invasiveness. Nature Structural & Molecular Biology, 19, 1139-1146. doi:10.1038/nsmb.2390
[26] Wu, C.F., Tan, G.H., Ma, C.C. and Li, L. (2013) The non-coding RNA llme23 drives the malignant property of human melanoma cells. Journal of Genetics and Genomics, 40, 179-188. doi:10.1016/j.jgg.2013.03.001
[27] Eswaran, J., Horvath, A., Godbole, S., Reddy, S.D., Mudvari, P., Ohshiro, K., et al. (2013) RNA sequencing of cancer reveals novel splicing alterations. Scientific Reports, 3, Article ID: 1689. doi:10.1038/srep01689

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.